End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
770,000 KRW | -1.28% | -1.41% | +1.32% |
Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
Apr. 25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
Sales 2024 * | 4,263B 3.1B | Sales 2025 * | 4,915B 3.57B | Capitalization | 54,804B 39.84B |
---|---|---|---|---|---|
Net income 2024 * | 982B 714M | Net income 2025 * | 1,183B 860M | EV / Sales 2024 * | 12.4 x |
Net cash position 2024 * | 2,085B 1.52B | Net cash position 2025 * | 2,961B 2.15B | EV / Sales 2025 * | 10.5 x |
P/E ratio 2024 * |
55.8
x | P/E ratio 2025 * |
47.6
x | Employees | 4,284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
1 day | -1.28% | ||
1 week | -1.41% | ||
Current month | -7.34% | ||
1 month | -7.00% | ||
3 months | -0.39% | ||
6 months | +5.62% | ||
Current year | +1.32% |
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 770,000 | -1.28% | 82,298 |
24-04-25 | 780,000 | -1.27% | 68,732 |
24-04-24 | 790,000 | -0.13% | 48,667 |
24-04-23 | 791,000 | -1.37% | 44,112 |
24-04-22 | 802,000 | +2.69% | 59,922 |
End-of-day quote Korea S.E., April 25, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.32% | 40.42B | |
-4.66% | 87.53B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B | |
+2.29% | 7.67B |
- Stock Market
- Equities
- A207940 Stock